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Abstract Recent mechanistic insights obtained from pre-
clinical studies and the approval of the first immunotherapies
has motivated increasing number of academic investigators
and pharmaceutical/biotech companies to further elucidate
the role of immunity in tumor pathogenesis and to reconsider
the role of immunotherapy. Additionally, technological
advances (e.g., next-generation sequencing) are providing
unprecedented opportunities to draw a comprehensive pic-
ture of the tumor genomics landscape and ultimately enable
individualized treatment. However, the increasing com-
plexity of the generated data and the plethora of bioinfor-
matics methods and tools pose considerable challenges to
both tumor immunologists and clinical oncologists. In this
review, we describe current concepts and future challenges
for the management and analysis of data for cancer immu-
nology and immunotherapy. We first highlight publicly
available databases with specific focus on cancer immunol-
ogy including databases for somatic mutations and epitope
databases. We then give an overview of the bioinformatics
methods for the analysis of next-generation sequencing data
(whole-genome and exome sequencing), epitope prediction
tools as well as methods for integrative data analysis and
network modeling. Mathematical models are powerful tools
that can predict and explain important patterns in the genetic
and clinical progression of cancer. Therefore, a survey of
mathematical models for tumor evolution and tumor–
immune cell interaction is included. Finally, we discuss
future challenges for individualized immunotherapy and
suggest how a combined computational/experimental
approaches can lead to new insights into the molecular
mechanisms of cancer, improved diagnosis, and prognosis of
the disease and pinpoint novel therapeutic targets.
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Introduction
Recent mechanistic insights obtained from preclinical
studies and the approval of the first immunotherapies have
motivated increasing number of academic investigators and
pharmaceutical/biotech companies to further elucidate the
role of immunity in tumor pathogenesis and to reconsider
the role of immunotherapy. Several factors contributed
considerably to this renaissance phase of cancer immu-
nology and immunotherapy [1].
First, major advances in immunology over the past
30 years improved our understanding of the complex
interaction between the immune system and the tumor [2].
The immune system can respond to cancer cells by reacting
against tumor-specific antigens or against tumor-associated
antigens. The antigenic determinants, epitopes, are pre-
sented on the cell surface, where they can be recognized by
T cells or antibodies, eventually eliciting tumor destruction
or enforcing proliferation. Cancer immunosurveillance is
considered to be an important host protection process to
inhibit carcinogenesis and to maintain cellular homeostasis
[3]. Extensive work in experimental systems has elucidated
some of the mechanisms underlying spontaneous antitumor
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immunity and has formed the basis for the cancer immu-
noediting hypothesis. This hypothesis divides the immune
response to cancer into the ‘‘three E’s’’ which are elimi-
nation, equilibrium, and escape [4–6].
Second, there is increasing clinical evidence that the
immune system influences the recurrence of cancer. For
example, our previous results have shown the close cor-
relation between the ‘‘high’’ intra- and peri-tumoral adap-
tive immune reaction in colorectal carcinoma and a good
prognosis, and inversely, a ‘‘low’’ density of T cells was
correlated with a poor prognosis [7, 8]. In fact, of all the
various clinical and histopathologic criteria currently
available, the immune T cell infiltrate was shown to be the
most important predictive criteria for survival [7–9].
Third, FDA approval of two cancer immunotherapies:
(1) ipilimumab antibody directed against CTLA-4, a mol-
ecule that downregulates T cell activation for the treatment
of melanoma, and (2) sipuleucel-T, a therapy consisting of
autologous PBMC activated with the prostatic acid phos-
phatase; prostate cancer–associated antigen fused to
GM-CSF for the treatment of patients with advanced hor-
mone-refractory prostate cancer. Over and above, recent
promising results for the blockade of programmed death 1
(PD-1), an inhibitory receptor expressed by T cells
[10, 11], are likely to provide a new benchmark for anti-
tumor activity in immunotherapy and will initiate a number
of studies for future multimodal therapy. Historically, the
treatment methods for the different types of cancers were
surgery, radiation therapy, chemotherapy, or combinations
of these to limit the progression of malignant disease. The
fourth modality of immunotherapy is now starting to be
used in clinical practice and will become a standard
treatment for a variety of cancers [2, 12].
Fourth, recent technological advances [e.g., next-gen-
eration sequencing (NGS)] are providing unprecedented
opportunities to draw a comprehensive picture of the tumor
genomics landscape and ultimately enable individualized
treatment. Due to the rapid declination of costs per base
pair, NGS projects are now affordable even for small- to
mid-sized laboratories. Point mutations, chromosomal
rearrangements, translation from cryptic start sites or
alternative reading frames, splicing aberrations, and over-
expression have all been reported as sources of tumor
antigens [3, 13, 14] and can be now readily detected. It is
noteworthy that recent study showed a proof-of-concept in
which somatic mutations are first detected using NGS, then
the immunogenicity of these mutations is defined, and
finally, mutations are tested for their capability to elicit T
cell immunogenicity [15]. Thus, tailored vaccine concepts
based on the genome-wide discovery of cancer-specific
mutations and individualized therapy seem technically
feasible.
However, the increasing complexity of the generated
data and the plethora of bioinformatics methods and tools
for the analysis pose considerable challenges. In this
review, we describe current concepts and future challenges
for the management and analysis of data for cancer
immunology and immunotherapy. We first highlight pub-
licly available databases with specific focus on cancer
immunology including databases for somatic mutations
and epitope databases. We then give an overview of the
bioinformatics methods for the analysis of next-generation
sequencing data (whole-genome and exome sequencing) as
well as bioinformatics tools for epitope prediction, inte-
grative data analysis, and network modeling. Mathematical
models are powerful tools that can predict and explain
important patterns in the genetic and clinical progression of
cancer. Therefore, a survey of mathematical models for
tumor evolution and tumor–immune cell interaction is
included. Finally, we discuss future challenges for indi-
vidualized immunotherapy and suggest how a combined
computational/experimental approaches can lead to new
insights into the molecular mechanisms of cancer,
improved diagnosis, and prognosis of the disease and
pinpoint novel therapeutic targets.
Data sources
The continuous improvement of existing technologies for
large-scale data generation like microarrays and proteo-
mics, as well as the development of novel powerful tech-
nologies including NGS and high-content techniques, led
to an increased use in cancer research. Figure 1 illustrates
the data and information flow in contemporary cancer
immunology research and, in near future, also in person-
alized cancer immunotherapy. Without surprise, within the
last few years, the amount of data generated and deposited
in publicly available databases exploded. Thus, a cancer
researcher can address today a specific question and not
only by generating proprietary high-throughput data but
also by accessing and mining available datasets. We
therefore describe cancer databases and databases for
cancer immunology.
Cancer databases
The volume of post-genomic data has resulted in the cre-
ation of a plethora of resources for cancer research com-
munity and lead to innovative approaches to cancer
prevention [16]. We summarized major sites where these
data sets can be assessed in Table 1. Note that the contents
of the databases are not exclusive for a specific molecular
type and are partly redundant.
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Cancer genomic data sources can be divided as follows:
(a) Databases harboring gene/microRNA expression pro-
files The discovery of gene/microRNA expression
patterns provides better predictions of clinical out-
come than traditional clinicopathologic standards [31]
and can be used for molecular classification of human
cancer [32, 33].
(b) Databases for copy number of variations (CNV)
Results generated using various reliable platforms
including NSG for high-resolution detection of DNA
copy number changes are available [31, 34, 35]. The
publicly available data generated with diverse plat-
forms are given in the second column.
(c) DNA mutation detection databases All cancers arise
as a result of the acquisition of a series of fixed DNA
sequence abnormalities. These abnormalities include
base substitutions, deletions, amplifications, and
rearrangements [36]. Thus, the strongest predictors
of risk of developing cancer and of response to
therapy appear to be at the DNA level [31].
Databases were designed to store, manage, organize,
and present the information on somatic mutations in
cancer (i.e., COSMIC, caSNP, dbSNP). For example,
COSMIC database describes somatic mutations
information relating to human cancers. Recently,
genome-wide somatic mutation content of tumor
samples, including structural rearrangements and
non-coding variants, has been included. COSMIC
is now integrating this information into the database,
providing full coding and genomic variant
annotations for samples, both from CGP laboratories
and recent publications [19].
(d) Epigenetic profiles databases The datasets include
histone acetylation, histone methylation, and DNA
methylation. These modifications are now thought to
play important roles in the onset and progression of
cancer in numerous tumor types [37].
(e) Databases with integrative analyses These databases
provide results representing analysis of data across a
cohort of samples where statistical methodologies and
computational algorithms were applied to identify
molecular subtypes from various data sources [38].
For example, the Cancer Biomedical Informatics Grid
(caBIG) aims to provide a common informatics plat-
form to the cancer research community by integrating
heterogeneous datasets and the provision of open access
interoperable tools (i.e., caArray, caGWAS) [16].
(f) Databases with other data types Finally, there are
databases with other types of data (i.e., mouse models,
phenotypic data, networks, proteomics) also aiming at
collecting and providing insights into the mechanism
of cancer development [38]. For example, Cancer
Model Database (caMOD) provides information about
animal models for human cancer [39] to the research
community.
Epitope databases
There are a number of publicly available databases con-
taining experimentally and computationally derived
Fig. 1 Data and information
flow in cancer immunology
research. The datasets are
integrated from clinical
observations, medical records,
‘‘omic’’ technologies, and the
next-generation sequencing
technology and analyzed by
using bioinformatics methods.
Cancer researchers are using
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information on T cell and B cell epitopes, binders to the
major histocompatibility complex (MHC) molecules, and
the transporter associated with antigen processing (TAP)
(Table 2). Since there is a considerable overlap between
the databases, we calculated the unique entries by filtering,
formatting, and merging the contents of the databases. This
analysis shows that there are currently about 35,000 entries
for human peptides (Fig. 2).
Bcipep [50] and CED [41] are sources of B cell epi-
topes, linear and conformational, respectively. Both of
them offer a descriptive measure of epitope immunoprop-
erty. IEDB [46], MHCBN [47], and SYFPEITHI [49] are
currently the largest repositories. IEDB is most frequently
maintained, well annotated, and supplies broad informa-
tion. It is easily queryable for tumor-related information
and provides extensive experimental details. The epitope
immunogenicity is quantified with affinity measures, T cell
activity, or antibody binding assays. It is generated from
automatically compiled publications that describe epitopes,
which are classified using machine learning methods, and
subsequently manually curated by senior immunologists.
However, since cancer is not one of the priority diseases,
for this database, cancer-related literature is not yet com-
prehensively covered. Thus, despite IEDB’s large size, the
contents of other databases are complementary.
Unlike IEDB, MHCBN also contains information on
TAP binders, in addition to peptides binding to MHC
molecules. Moreover, not only the positive examples of
binding proteins are collected from the literature and the
available databases, but also non-binding peptides are
included. It is a rich source of information, where the
immunogenicity of the peptides is quantified with cate-
gorical measures (low, medium and high) of binding
affinity and T cell activity; nevertheless, there is still space
for improvement, for example, a more comprehensive
source-protein description could alleviate interpretation.
Smaller but similar to MHCBN is EPIMHC [45], also
neglecting rich source-protein annotation.
SYFPEITHI has evolved from the first collection of
MHC ligands into one of the largest databases. It has
contributed significantly to our understanding of binding
motifs and to the advances in development and validation
of epitope prediction. It has been continuously maintained
for more than 20 years. The constitutive MHC binders and
T cell epitopes are gathered from the literature and each of
them described with anchors and auxiliary anchor amino
acids.
Databases developed specifically to serve for cancer
vaccine target discovery are Peptide Database [48], TAN-
TIGEN, DFRMLI [44], CIG-DB [42], and CTDatabase
[43]. Peptide Database not only provides manually curated
list of T cell-defined tumor antigens but also categorizes
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specific [48]. CTDatabase presents only antigens from the
last category, also referred to as Cancer-Testis. TANTI-
GEN follows the proposed scheme for antigen classifica-
tion. Additionally, it is much more abundant and focuses
on antigen annotation. It contains experimentally validated
HLA ligands and T cell epitopes accompanied with the
original sequence and a detailed description of the source
human tumor antigens, such as multiple sequence align-
ment of the isoforms, gene expression profiles, database
IDs in COSMIC or SwissProt for the causing substitution
mutations. CIG-DB performs literature mining, training,
and clustering to semi-automatically classify T cell
receptors (TCR) and immunoglobulins (IG) for human and
mouse into two groups: cancer therapy and hematological
tumors. Additionally, it aggregates publicly available epi-
tope sequences that interact with IG and TCR. An inter-
esting initiative of the Dana-Farber institute is DFRMLI, a
repository of immunological data sets from major public
databases, intended for training and testing of machine
learning methods [44].
All of the databases are populated with experimentally
derived information supplied in the literature, with the
exception of MHCBN and EPIMHC, which include
information from available databases. There has been one
attempt for computational derivation of T cell epitopes,
catalogued in the HPtaa [51] database; however, it is cur-
rently not maintained and its access is impeded.
Bioinformatics tools for cancer immunology
and immunotherapy
The management and analysis of data generated with
‘‘standard’’ technologies like microarrays including SNP
arrays and array CGH arrays has been subject of previous
reviews [52–56]. In this paper, we therefore highlight NGS
data analysis, since this methodology is gaining increasing
popularity. Moreover, whole-genome or whole-exome
sequencing provides also information of single-nucleotide
variants, which can be further used to predict epitopes.
Epitope prediction tools were then reviewed followed by
methods for integrative data analyses and network
modeling.
Next-generation sequencing
Next-generation sequencing (NGS) has emerged with a great
power to provide novel and quantitative insights into the
molecular machinery inside the tumor cell. In addition to
expression profiling of transcripts and genes, and detection of
alternative splicing, it has enabled the discovery of single-
nucleotide variants (SNV), insertions, amplifications, dele-
tions, and inter-chromosomal rearrangements in the whole
genome and transcriptome. Its potential for cancer is very far
from being fully exploited, having the anticipated single-cell
sequencing, for example, already appearing on the horizon.
Sophisticated bioinformatics methods for analysis and
interpretation of tumor sequencing data are therefore of
utmost importance.
The tumor is genomically unstable. Altered ploidy,
tumor heterogeneity, and normal contamination are only a
few of the features characterizing the tumor sequencing
data that prompt the need for new and sophisticated bio-
informatics approaches. For example, according to the
experience of our and other labs, the different mutation
rates, allelic frequencies and structural rearrangements
across cancer types, subtypes, and within the tumor itself,
fail to meet the assumptions underlying the statistical
methods for SNV discovery in rare diseases. Therefore,
most of the currently available tools for mutation detection
show limited accuracy and small overlap. A step higher to
RNA level brings additional challenges for detection of
somatic mutations, such as post-transcriptional modifica-
tions, RNA fidelity, allele-specific expression, and
expression levels ranging between extreme values. How-
ever, analyses of RNA-Seq data are complex, and we refer
the readers to a recent review [57].
Whole-genome sequencing and whole-exome sequenc-
ing have proven to be valuable methods for the discovery
of the genetic causes of rare and complex diseases.
Although cheaper than Sanger sequencing, whole-genome
sequencing remains expensive on a grand scale. Over
and above, one sequencing run provides enormous amount
of data and poses considerable challenges for the analysis
and interpretation. In contrast, whole-exome sequencing
becomes a popular approach to bridge the gap between
genome-wide comprehensiveness and cost-control by
capturing and sequencing approximately 1 % of the human
genome that codes for protein sequences.
The complete whole-genome or whole-exome sequence
data analysis process is complex, includes multiple pro-
cessing steps, is dependent on a multitude of programs and
databases, and involves dealing with large amounts of
heterogeneous data. Currently, there are 168 individual
tools addressing some of the required analysis steps, 13
complete pipelines, and 11 workflow systems. Combining
different tools and methods for analysis to obtain biological
meaningful results presents a challenge. These problems
can be eased by using comprehensive and intuitive pipe-
lines that consist of combination of software tools, which
are capable of analyzing all steps starting from raw
sequences to a set of final annotations.
However, not all pipelines cover essential steps of read
alignment, variant detection, and variant annotation. We
therefore describe only the pipelines covering the entire
analysis workflow: HugeSeq [58], Treat [59], and
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SIMPLEX [60]. HugeSeq is a fully integrated pipeline for
NGS analysis from aligning reads to the identification and
annotation of all types of variants (SNPs, Indels, CNVs,
SVs). It consists of three main parts: (1) preparing and
aligning reads, (2) combining and sorting reads for parallel
processing of variant calling, and (3) variant calling and
annotating. Treat is a pipeline where the user can use each
of the three modules (alignment, variant calling, and var-
iant annotation) separately or as an integrated version for
an end-to-end analysis. It provides a rich set of annotations,
html summary report, and variant reports in Excel format.
SIMPLEX [60] is an autonomous analysis pipeline for the
analysis of NGS exome data, covering the workflow from
sequence alignment to SNP/DIP identification and variant
annotation. It supports input from various sequencing
platforms and exposes all available parameters for cus-
tomized usage. It outputs summary reports and annotates
detected variants with additional information for discrim-
ination of silent mutations from variants that are potentially
causing diseases.
In contrast to the pipelines described above, workflow
management systems are specifically designed to compose
and execute a series of data manipulation or analysis steps.
Most existing systems provide graphical user interfaces
allowing the user to build and modify complex workflows
with little or no programming expertise. Galaxy [61] is a
web-based platform where the user can perform, reproduce,
and share complete analyses. Pipelines are represented as a
history of user actions, which can be stored as a dedicated
workflow. It contains over a hundred analysis tools and
users can add new tools and share entire analysis steps and
pipelines. The Taverna [62] workflow management system
stores workflows in a format that is simple to share and
manipulate outside the editor. Initially, it did not ship with
any prepackaged NGS analysis tools and integrating tools
requires some programming experience. LONI [63] is a
workflow processing application that can be used to wrap
any executable for use in the environment. In order to
access the tools, users need to connect to either public or
private pipeline servers.
Epitope prediction tools
Point mutations, chromosomal rearrangements, translation
from cryptic start sites or alternative reading frames,
splicing aberrations, and over-expression have all been
reported as non-conventional sources of antigens [64, 65].
Regardless of whether these genetic changes contribute to
oncogenesis or not, they could affect the immune response.
For the first time, comprehensive characterization of the
tumor genotype is enabled by sophisticated computational
analysis of deep-sequencing data. The mutational signa-
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immune activity, in order to detect vaccine target candi-
dates or to predict response to therapy.
Somatic amino acid substitutions and short DNA dele-
tions and insertions that reside in exons result with changes
in the protein sequences that could eventually be discrim-
inated as non-self and potentially trigger anti-tumor
behavior. Mutations could be a source of novel peptides
that are presented on the cell surface by MHC molecules,
where they can be recognized by T helper or cytotoxic T
lymphocytes (CTL). To obtain a set of potentially immu-
nogenic peptides, sequence windows spanning each newly
introduced amino acid should be extracted, with window
sizes incremented within the known epitope length range.
These sequence fragments are then analyzed by epitope
prediction tools. An alternative method is based on anti-
gen–antibody interactions which play an important role in
human immune response. In case when conformational
epitopes are sought, the whole mutated antigen sequence is
analyzed, as opposed to sequence windows, since potential
structural changes should also be considered.
Epitope prediction has been a subject of study for many
years, and it remains an active area of research. Many new
methods have been published, and the existing tools have
been considerably improved. The growth of experimental
data has enabled the use of more sophisticated methods,
resulting in increased prediction accuracy. Furthermore,
the diversity of MHC molecules that can be studied has
also increased. Binding predictions are now available for
hundreds of MHC alleles, resulting in the coverage of the
majority of the population. There is a plenty of reviews
describing the technical background of the prediction
algorithms [66–68]. Here, we describe freely available,
state-of-art tools that currently stand out in the huge rep-
ertoire of methods.
T cell epitope prediction
The initial attempts for epitope prediction aimed at esti-
mation of MHC binding affinity, for the purpose of
reducing the list of candidate T cell epitopes. Since then,
much of the efforts have been invested into MHC binding
prediction. It starts with the binding motifs [49], when
experimentally confirmed binders are used to create a
matrix, where each element represents a score for one
amino acid at a given position. The highest score is
assigned to amino acids that frequently reside at the anchor
position. The scores decrease reversely to frequency of
occurrence of the residue down to the minimum score for
amino acids that are unfavorable for binding. Later, it was
confirmed that MHC binding is the best indicator of
immunogenicity, and therefore, the first prediction methods
are still popular. The matrix-based methods: SYFPEITHI
[49] for MHC class I and II binding prediction, and BIMAS
[69], intended for identification of HLA-class I binders, are
widely used, particularly for prediction of HLA-A*0201
restricted epitopes [70–73]. Being one of the most frequent
HLA-class I allele, HLA-A*0201 has been the first and the
most widely studied. The peptides that should be selected
Fig. 2 Databases for epitopes
and calculation of the total
number of epitopes. Shown are
available databases and the
number of entries in each
database (see text for
abbreviations). Since there is a
considerable overlap between
the databases, we have analyzed
the data and as of to date
identified the number of unique
peptide sequences to be around
35,000. The number of entries
per database refers only to
human peptide sources
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are the 2 % of the highest scoring predictions, because they
are expected to contain naturally presented T cell epitopes
[69, 74], in more than 80 % of the cases for SYFPEITHI
[74].
This approach assumes that each amino acid at a par-
ticular position contributes to the MHC-peptide complex
stability independently of the other amino acids, which is
considered as its main limitation. The growth of experi-
mental data enabled the use of elaborated machine learning
methods that capture the patterns of amino acid depen-
dencies in the sequence. Among the matrix-based tools,
stabilized matrix method (SMM) [75] and NetMHC [76]
stand out for their performance [77, 78] and have been
continuously upgraded. The outcome of the higher-order
methods depends on the training set, for example the range
of peptide lengths they output is limited to the peptide
lengths used for training, which is small for long MHC
class II peptides. However, given an appropriate training
datasets, the higher-order methods are also more accurate.
The binding strength to the MHC class I molecules has
been proved to be the most restrictive step for immuno-
genicity prediction and to be the easiest to estimate from
the peptide sequence. However, the remaining components
in the antigen presenting pathway can be used to increase
the prediction confidence. There are tools that predict MHC
class I pathway events, such as proteasomal cleavage and
TAP transport efficiency. TAP binding should be consid-
ered with caution, because it might not be the best choice
for HLA-A2 binder prediction since around 10 % of the
HLA-A2 restricted peptides are transported to the endo-
plasmic reticulum independently of TAP. The proteasomal
cleavage tools predict potential cleavage sites or most
probable peptide fragments. Standalone tools for prote-
asomal cleavage and TAP transport did not reach as
widespread acceptance as MHC prediction tools, because
these events are more complicated to model and alternative
pathways also interfere. In spite of that, they have con-
tributed to greater prediction power when integrated with
MHC binding predictors [79].
The tools for MHC class II binding exhibit declined
performance, owing to the variable length of the peptides
that bind to the open groove of the MHC class II molecule.
As mentioned above, SYFPEITHI can be used for MHC
class II prediction. However, it is only limited to peptides
with length of 8–11 and 15 and offers small allele cover-
age. Tools that overcome these limitations and exhibit
relatively high accuracy are netMHCIIpan [80] and
TEPITOPEpan [81]. TEPITOPEpan is the predecessor of a
recent upgrade of the once-most-popular tool for MHC
Class II binding prediction, TEPITOPE. It is able to detect
only HLA-DR binders, more than 700 allele types, shows
comparable accuracy to NetMHCIIpan, and performs well
in predicting binding cores.
SYFPEITHI, BIMAS, and IEDB AR occur in the
majority of published papers. Even though there are more
refined methods claiming higher accuracy, SYFPEITHI
and BIMAS remain to be widely used. The explanation
could be that they have shown good performance on HLA-
A2 restricted peptides, and HLA-A2 is the most abundant,
and hence, the most studied human serotype. Pan-specific
methods represent state of the art [80–82]. Lack or scarcity
of experimental binding information for HLA alleles, for
which the sequence is known, is not a limitation anymore.
This is achieved by using the peptide sequence and the
contact information for the corresponding MHC molecule
to train the algorithm. In this way, the algorithm is able to
recognize binding potential to uncharacterized MHC mol-
ecules. Benchmark studies have estimated NetMHCpan as
the most accurate pan-specific MHC binding predictor [83]
and NetCTLpan as the best performing integrated approach
[82].
B cell epitope prediction
The predictive performance of B cell epitope prediction
methods has only gradually advanced over the years [84].
BepiPred predicts linear B cell epitopes by combining a
hidden Markov model and two propensity scores: Levitt’s
secondary structure and Parker’s hydrophilicity, achieving
an AUC of 0.6 [85]. ABCPred [86] is another linear B cell
predictor that achieves accuracy of *66 % in the best case
by using recurrent artificial neural networks. Choosing an
epitope selection threshold for these methods requires a
trade-off between sensitivity and specificity.
Most of the tools for prediction of conformational B cell
epitopes require the protein structure of the antigen. Nor-
mally, the structure of the novel protein sequence resulting
from genetic alterations in the tumor is not known. In such
cases, sequence-based methods and auxiliary tools for
structure prediction are convenient. CBTope [87] is a
Support Vector Machine model trained on experimentally
verified protein chains to detect antibody interacting resi-
dues. Thus, it requires only the antigen sequence as input.
It reports a very high maximum accuracy of more than
85 % (AUC 0.9). The biggest drawback of CBTope is that
it does not discriminate the epitope coordinates from the
antigen. ElliPro [88] is more convenient method for this
purpose. It generates a list of predicted linear and confor-
mational epitopes. It was shown that the method overper-
forms 6 other structure-based methods with an AUC of
0.732 [88]. In case of a missing protein structure, the tool
accepts protein sequence as input, which is then compared
with structural templates in PDB using BLAST. A user-
defined number of best-hit structural templates are used to
model a 3D structure of the submitted sequence by
MODELLER [89]. It identifies the components of the
Cancer Immunol Immunother (2012) 61:1885–1903 1895
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conformational B cell epitopes as clusters of neighboring
residues based on their protrusion index values.
Integrated data analysis and network modeling
Utilizing various high-throughput technologies for char-
acterizing the genome, epigenome, transcriptome, prote-
ome, metabolome, and interactome enables one to
comprehensively study molecular mechanisms of cancer
cells and their interactions with the immune system. The
real value of the disparate datasets can be truly exploited
only if the data are integrated. To our experience, it is of
utmost importance to first set up a local database hosting
only the necessary data. Only preprocessed and normalized
data are stored in a dedicated database whereas primary
data are archived at separate locations including public
repositories. Although it is tempting to upload and analyze
all types of data in a single system, experience shows that
primary data are mostly used once. This approach is even
more advisable for large-scale data including microarrays,
proteomics, or NGS data. However, links to the primary
data need to be secured so that later re-analyses using
improved tools can be guaranteed. In this context, it is
noteworthy that in the majority of published studies, the
analyses were based on medium-throughput data, meaning
that the number of analyzed molecular species was in the
range of 100–1,000 (after filtering and pre-selection). With
this number of elements, the majority of the tools perform
satisfactorily on a standard desktop computer.
Once the data are integrated, that is, preprocessed and
deposited in a dedicated database, tools for integrative data
analysis can be applied. Only then, the results of the inte-
gration of these heterogeneous datasets will provide cancer
biologists with an unprecedented opportunity: to manipu-
late, query, and reconstruct functional molecular networks
of the cells [90]. One of the most common computational
approaches to delineate functional interaction networks is
based on Bayes integration [91, 92] or on a statistical
method for combination of p values from individual data
sets [93]. Additionally, network and graph theory can be
applied to describe and analyze the complexity of these
biological systems and subsequently visualize the networks
[94, 95]. For example, to reconstruct gene co-expression
networks, genes (nodes) with similar global expression
profiles over samples (tumor/patients) are connected, and
innovative methods can be then used to identify key tran-
scriptional regulators (ARACNe [96], MINDy [97]).
In addition to gene expression, a number of different
datasets can be integrated into networks, highlighting fur-
ther information otherwise hidden in the complex data sets.
Especially, protein–protein interaction data provide a
meaningful complementary source and can be applied to
identify relevant biological effects at the network level [53,
98]. In cancer research, a number of network modeling
approaches showed to be very promising [99–104]. These
network approaches enable also the inclusion of clinical
data from patients, which can comprise collected data
during standard treatment procedures, and during clinical
trials include histopathology, cancer stages and scores,
prognosis (survival time, relapse time), cancer subtypes,
and cancer biology parameters like ER-status for breast
cancer [53].
More recently, NGS (large-scale tumor–resequencing
and whole-genome exome sequencing studies) has added a
new dimension to cancer research and revolutionized our
ability to characterize cancers at the gene and transcript
and epigenetic levels and enables identification of immu-
nogenic tumor mutations targetable by individualized
vaccines [15, 105]. A number of integrated genome anal-
yses approaches have recently performed on several cancer
types and cohorts of patients [106–117] (see in particular
The Cancer Genome Atlas (TCGA)). Using these resulting
human genome data sets in conjunction with bioinformat-
ics tools, it is possible to predict biological meaning by
searching for substantially altered pathways, missense
mutations that are likely to be oncogenic, or regions of
altered copy numbers [106]. For this specific purpose,
recently tools were developed to address which cancer
genome alterations are functionally important, what path-
ways are affected, or what are the mutations likely to be
drivers in tumor progression (NetBox [118], DriverNet
[112], MEMo [119], PARADIGM [120], CHASM [121],
GISTIC [122], VarScan2 [123], CONEXIC [124]).
In summary, to gain further insight into a disease state
and suggest treatment strategies integrative analysis is
inevitable [125]. For example, Curtis et al. [107] presented
an integrated analysis of copy number and gene expression
in a discovery and validation set of primary breast tumors
from 2,000 patients with long-term clinical follow-up.
Their results provided a novel molecular stratification of
the breast cancer population, derived from the impact of
somatic copy number aberrations on the transcriptome.
Similarly, Ascierto et al. [126] performed comparative
analysis and validated the 5 genes signature of immune
response of breast cancer in two cohorts to determine
whether some patients with relapse may also show
expression of the immune function genes in their tumors.
Mathematical modeling in tumor immunology
and cancer immunotherapy
Modeling has been successfully applied in physiology for
many decades, but only recently the quality and the
quantity of biomolecular data became available for the
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development of causative and predictive models. Due to
their importance cancer in general, tumor immunology and
cancer immunotherapy in particular have also been in the
focus of theoretical investigators. For example, application
of theoretical techniques and the postulation of the ‘‘two
hit’’ hypothesis in the early 1970s led to the identification
of tumor-suppressor genes [127]. Later, in a landmark
paper, it was shown that cancer results from evolutionary
processes occurring within the body [128]. The theoretical
field of cancer immunology and immunotherapy experi-
enced similar development as the experimental: enthusiasm
phase in the 1970s and 1980s, skepticism phase from mid-
1980s to the end of last century, and recent renaissance
phase. The availability of genomic and other types of
quantitative data has recently driven the development and
application of a number of mathematical models of both
types, descriptive and mechanistic. In this review, we are
focusing on two areas in which mathematical modeling has
seen recent great progress: (a) modeling clonal evolution in
cancer, and (b) modeling tumor-immune cell interaction.
Modeling clonal evolution in cancer
Cancer progression is an evolutionary process [97] that
results from accumulation of genetic and epigenetic vari-
ations in a single somatic cell. These variations are heri-
table and can provide the cell with a fitness advantage. The
genetic changes produce phenotypic changes associated
with increased proliferation capabilities, decreased death,
enhanced migration and invasion, evasion of the immune
system, or the ability to induce angiogenesis. Cells with
advantageous mutations eventually outgrow competing
cells and tumor development proceeds by successive clonal
expansions. In each clonal expansion, additional mutations
are accumulated that drive cancer progression and lead to
more invasive phenotypes. New mutations cause the
simultaneous presence of multiple subclones of cells at
different malignancy levels, all sharing a common ances-
tor, which leads to tumor heterogeneity [129].
Because of its importance, the dynamics of the clonal
cancer progression has been the subject of several mathe-
matical studies [130–134]. Mathematical models may be
used to address some of the important biological questions,
such as understanding the mechanism of cancer initiation,
progression, distinguishing driver from passenger muta-
tions, defining the order of the genetic changes during
progression, and understanding the therapeutic resistance.
An in-depth review of the models has been recently pub-
lished and is beyond the scope of this paper [135]. Here, we
focus on recent studies with clinical implications.
The earliest approaches were models where mutations
accumulate in a population of constant size, considering
only one or two mutations [131, 134]. More recent studies
have focused on the waiting time to cancer [136, 137], that
is, the time until a critical number of driver mutations are
accumulated and initiate the growth of carcinoma and have
attempted to quantify the selective advantage of the driver
mutations [130, 132, 133].
Beerenwinkel et al. [132] related the waiting time to the
population size, mutation rate, and the advantage of the
driver mutations and showed that selective advantage of
mutations has the largest effect on the evolutionary
dynamics of tumorigenesis. In a recent study, Bozic et al.
[130] provided an equation for the proportion of expected
passenger mutations versus the proportion of the drivers
and estimated that driver mutations give an average fitness
advantage of 0.4 %. Martens et al. [133] found that spatial
structure, compared with non-structured cell populations
assumed in other studies, increases the waiting time.
Additionally to the identification of the driver mutations
and their selective advantage, it is also important to
determine the order in which genetic events accumulate in
tumors. The order can vary among tumors and even among
different compartments of the same tumor and might
explain important events in carcinogenesis. Early muta-
tions are promising therapeutic targets, and late mutations
are important in metastasis. Several mathematical models
have been developed to define this order and explain
important events in carcinogenesis [138, 139]. For exam-
ple, Gerstung et al. [140] used a probabilistic graphical
model and their results showed stronger evidence for
temporal order on pathway level than on gene level, indi-
cating that temporal ordering results from selective pres-
sure acting at the pathway level [140].
Another important clinical problem in cancer research is
the development of resistance to targeted therapies. Several
models have been developed to explain the evolutionary
dynamics of drug resistant cancer cells [141, 142]. In a
recent study, Diaz et al. [143] showed that tumors became
resistant to anti-EGFR antibodies as a result of emergence
of resistance mutations in KRAS and other genes that were
present in clonal subpopulation within the tumors before
the initiation of the treatment.
The dynamics of cancer progression is determined not
only by the mutations accumulating in the cells, but also by
the tumor’s interactions with the microenvironment. There
are several studies that use mathematical modeling to
quantify the interactions of the tumor cells with the sur-
rounding environment [144, 145]. In 2008, Gatenby et al.
[146] proposed a model that identifies six microenviron-
mental barriers that tumor has to overcome to emerge as an
invasive cancer. In another study, the authors used mod-
eling to quantify the interactions between tumor cells and
their surrounding stroma [147]. Their results showed that
the evolution of invasiveness occurs by coupling prolifer-
ation and motility, as increased motility allows the
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cancerous cells to escape the microenvironmental restric-
tions that reduce their proliferation ability.
In summary, mathematical models can assist in the
investigation of the clonal evolution of cancer and can give
an important insight into the history of the disease.
Understanding the evolutionary forces that drive carcino-
genesis could lead to more effective methods for preven-
tion and therapy. Over and above, mathematical models
can predict and explain success or failure of anticancer
drugs [148] and will be an important tool for the design of
combination therapies and minimize drug resistance.
Modeling of tumor–immune cell interactions
There is long history of theoretical studies and simulation
techniques involving mathematical and computational
approaches to study tumor progression and tumor–immune
cell interaction. The used techniques include deterministic
models, stochastic models, Petri nets, cellular automata,
agent-based model, and hybrid approaches [149, 150]. A
summary of different mathematical and computational
techniques in cancer systems biology is given in a recent
review paper [149–152].
One of the issues addressed using mathematical models
in tumor–immune cell interaction was adoptive immuno-
therapy. Adoptive immunotherapy using tailored T cell
infusion to treat malignancies has been proven to be
effective in certain type of tumor [153–155]. However,
there are still many unanswered questions for example how
to generate a large number of tumor-specific T cells, how
many T cells to use for therapy, and what schedule would
be most effective [153]. Integrative mathematical modeling
of tumor-immune system interactions and immunotherapy
treatment could provide an analytical predictive framework
to address such questions.
The interplay of different cytokines like IL-2 and
transforming growth factors like transforming growth fac-
tor (TGF-b) is another aspect in the focus of theoretical
research. There are several mathematical models that spe-
cifically incorporate the effect of the TGF-b protein on
tumor development [156–159]. Recently, Wilson et al.
[160] developed a mathematical model to highlight the fact
that immunotherapy alone is not always effective in killing
a tumor. Their studies provide an initial analytical frame-
work for studying immunotherapy via TGF-b inhibition in
combination with vaccine treatment, which help popula-
tions of immune cells to expand during initial phases of
tumor presentation.
The effect of innovative new melanoma cancer therapies
was investigated using models based on systems of dif-
ferential equations [161]. Kirschner et al. [162] were one of
the first to illustrate through mathematical modeling the
dynamics between tumor cells, effector T cells, and IL-2.
They explored the effects of adoptive cellular immuno-
therapy on the model and described in which circumstances
the tumor can be eliminated. Other groups have developed
and investigated the effect of IL-2. De Pillis et al. [163]
proposed a sophisticated model involves tumor cells and
specific and non-specific immune cells (i.e., nature killer
(NK) cells) and employs chemotherapy and two types of
immunotherapy (IL-2 supplementation and CD8? T cell
infusion) as treatment modalities. In the later version of the
model, the concentrations of CD8? cells and the NK cells
of the model were changed. Then, it was possible to sim-
ulate the effect of endogenous IL-2 production on CD8?
cells and NK cells. Finally, it was shown that the potential
patient-specific efficacy of immunotherapy may be
dependent on experimentally determinable parameters
[164].
One of basic concepts of immunotherapy is the
improving of the ability of tumor-specific T lymphocytes.
Kronik et al. [153] presented a new mathematical model
developed for modeling cellular immunotherapy for mel-
anoma. They found that the tumor-immune dynamics
model provided minimal requirements (in terms of T cell
dose and T cell functionality) depending on the tumor
characteristics (tumor growth and size) for a clinical study
[153].
In most mathematical models, the tumor cells interact-
ing with the immune system were considered as homoge-
neous. Recently, Iwami et al. [165] implemented a model
with in which the dynamics of tumor progression under
immune system surveillance was investigated considering
the effects of increasing mutation rates. It could be shown
that there are three different thresholds depending on the
rate of mutations and the number of variants. Until the first
threshold is reached, the immune response suppresses all
tumor variants (phase of tumor dormancy). After reaching
the first threshold, some tumor cells are able to escape the
immune response (phase of partial immunoescape). If the
number of variants reaches the second threshold, all tumor
cells escape the immune response (phase of complete im-
munoescape). After reaching the third and last threshold
through the high number of variants, an error catastrophe
occurs. In this phase, the original tumor can no longer
expand the population and the original tumor cells go
extinct. After the examination of different treatment strat-
egies the model shows that combination of chemotherapy
and immunotherapy is the therapy that could lead to tumor
eradication and cure. To find the effective threshold of
cytokine and adoptive T cell therapy is not only important
to gain a broad understanding of the specific system
dynamics but will also help to guide the development of
combination therapies [163]. Kogan et al. [166] worked on
generalized mathematical modeling for high grad malig-
nant glioma-immune system interaction applied in
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untreated cases and under T cell immunotherapy. Their
models described the dynamic of tumor cells, T cells, and
quantities of secreted cytokines (TGF-b and IFN-c). They
also estimated a level of T cell infusion on a per-patient
basis, clinical measurements, which effects tumor size.
Moreover, their analysis suggested that the duration of
treatment is necessary for adoptive cellular therapy.
In summary, mathematical models of tumor-immune
interactions provide an analytical view of cancer systems
biology in order to address specific questions about tumor-
immune dynamics. In silico experimental models of cancer
have the potential to allow researchers to refine their
experimental programs with an aim of reducing costs and
increasing research efficiency [167].
Conclusion
This paper reviews bioinformatics methods used in a
contemporary cancer immunology research and cancer
immunotherapy. From the plethora of tools and methods
for the analysis of biomolecular data, we reviewed selected
topics which are of major importance for the field: dat-
abases, bioinformatics methods for NGS data, epitope
prediction, integrative data analysis and network modeling,
and mathematical models. Other topics are of similar
importance, but due to the page limitations, these are not
introduced. For example, digital pathology is gaining a
major impact in research, teaching, and routine applica-
tions [168]. New devices for automated staining and high-
resolution scanners are already in use and provide a wealth
of high-content data (i.e., images with [100 Gbytes per
slide). From these images, one can extract the number, the
location, and type of infiltrating T cells and define an
immune score, which is superior to the AJCC/UICC-TNM
staging [9]. Without doubt, this and similar type of image-
based information in combination with biomolecular
measurements will be of great importance in future clinical
practice. However, these datasets pose considerable tech-
nical challenges, which are only partially solved.
As of today, we and others strongly believe that NGS
data will not only enable the identification of novel genes
and pathways relevant for diagnosis and prediction of
tumor progression but will also be fundamental in the near
future in clinical practice. Specifically, whole-exome
sequencing is increasingly being used to characterize the
genomic landscape of the tumor showing a number of
novel insights into the biology of the cancer and identifying
novel therapeutic targets [169]. The current bottleneck in
whole-exome sequencing projects is not the sequencing of
the DNA itself but lies in the structured way of data
management and the sophisticated computational analysis
of the experimental data.
Cancer immunology research and cancer immunother-
apy add an additional layer of complexity and require a
specific solution. As NGS projects are delivering hundreds
or even thousands of germline and somatic mutations per
patient sample, automated tools are needed to process these
datasets and predict putative epitopes. The accuracy of
current T cell epitope predictors has reached a high level
and hence enables researchers to focus on a subset of
potential epitope candidates. To our experience, the overlap
of the output of the prediction tools is not always identical,
and we therefore recommend a consensus approach.
The ever-increasing amount of data as well as the het-
erogeneity and complexity of the datasets urge for inten-
sified use of bioinformatics tools and mathematical
methods. We strongly argue that only interdisciplinary
teams can extract the relevant information and so generate
knowledge from these datasets. Thus, wet-lab scientists
should consider data management at the very beginning of
the project and commit considerable resources to data
management and analysis for several reasons. First, science
is becoming increasingly driven by data as a source of
hypotheses, and the ability to integrate and analyze heter-
ogeneous data is crucial. Inclusion of additional data from
public sources and integration with proprietary data can
pinpoint novel molecular interactions. Second, specific
projects require specific database solutions to manage the
captured data and therefore specific adaptations and/or
developments of databases are of utmost importance. And
third, in our view, an approach by which biomedical
questions are addressed through integrating experiments in
iterative cycles with mathematical modeling, simulation,
and theory will considerably contribute to the field.
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